---
title: Geopolitics is turning second-site qualification into a baseline API CDMO requirement in 2026
slug: geopolitics-is-turning-second-site-qualification-into-a-baseline-api-cdmo-requirement-in-cdmo
site: cdmo
post_kind: deep_dive
byline: Carlton Hoyt
description: Most API outsourcing decisions used to compare one site against another on price, capability, and quality history. The 2026 sources describe a different question: which pair of sites, in which…
canonical_url: https://www.cdmo.directory/posts/geopolitics-is-turning-second-site-qualification-into-a-baseline-api-cdmo-requirement-in-cdmo
published_at: 2026-11-12T05:01:18.903Z
last_updated: 2026-11-12T05:01:20.567Z
---

Most API outsourcing decisions used to compare one site against another on price, capability, and quality history. The 2026 sources describe a different question: which pair of sites, in which regions, gets you through a disruption. A single excellent site is being treated as a concentration risk, not a finished answer.

That shift is documented more through commentary than through hard data. The evidence below is mostly trade-press analysis, vendor-authored content, and a press release. It agrees on direction, and it is thin on cost, timelines, and how often disruptions have actually hit supply. This essay separates what the sources support from what a buyer has to test in an RFP.

## What the sources agree on

The clearest statement comes from a cdmo.directory piece on [dual sourcing and second-site qualification](https://www.cdmo.directory/posts/api-cdmos-navigate-geopolitical-risk-dual-sourcing-supply-resilience-in-2026-cdmo). It calls dual sourcing, second-site qualification, and scenario-based contingency planning baseline expectations rather than optional risk tools. It also frames geopolitical risk as a structural feature of pharmaceutical manufacturing, not a temporary headwind. That is an editorial position, not a survey result, but it matches the other material.

A [PharmiWeb analysis of sanctions and disruptions](https://www.pharmiweb.com/press-release/2026-04-13/impact-of-geopolitical-tensions-sanctions-and-supply-chain-disruptions-on-contract-manufacturing-cdmocmo-and-pharma-outsourcing-trends) says geopolitical tension is restructuring global manufacturing, with regionalization, diversification, and risk mitigation visible across all major sectors. It is a press release, so read "all major sectors" as a claim, not a measurement.

Two Pharma's Almanac pieces go in the same direction. One identifies [geopolitical tensions, trade disputes, and instability](https://www.pharmasalmanac.com/articles/what-do-you-see-as-the-biggest-threat-to-the-cdmo-industry-in-2026-or-beyond) as continuing threats to timely, cost-effective delivery of APIs and intermediates. Vector Biomed's [threats-to-CDMOs page](https://vectorbiomed.com/resource/what-do-you-see-as-the-biggest-threat-to-the-cdmo-industry-in-2026-or-beyond/) carries the same wording. Treat those as one source, not two. The repetition reflects republication, not independent confirmation.

The phrase "intermediates" matters. Risk in an API program does not stop at the drug substance site. It runs upstream through starting materials and intermediates, which is where many buyers have the least visibility.

## BIOSECURE moved from forecast to shortlist filter

The most concrete development in the pack is regulatory. Pharma's Almanac, in its piece on [geopolitical sourcing and manufacturing decisions](https://www.pharmasalmanac.com/articles/how-are-geopolitical-factors-influencing-sourcing-and-manufacturing-decisions-for-2026-and-beyond), says the BIOSECURE Act effectively removed WuXi as a viable CDMO option for US-bound programs. It adds that companies are responding by diversifying supply chains and building redundancy into regions perceived as more stable.

Two cautions apply. First, "effectively removed" is the publication's characterization of practical sponsor behavior. It is not a statement about what any statute prohibits for a specific contract, so your regulatory counsel should confirm how the law applies to your program. Second, the source is about US-bound programs. If your commercial footprint is elsewhere, your exposure may differ, and the evidence pack does not address that.

Peptides show how this plays out in a single modality. PeptideStaff's [China peptide CDMO risk analysis](https://peptidestaff.com/news/china-peptide-cdmo-risk-analysis-2026/) says Western companies relying on Chinese CDMOs for peptide API face a complex 2026 risk landscape. It lists geopolitical tension, BIOSECURE implications, regulatory divergence, and supply chain resilience pressures. The publisher's commercial angle is unclear from the excerpt, so weigh it accordingly. The useful point is the combination of risks. A program can be exposed to policy risk, regulatory divergence, and resilience risk at once, and each one calls for a different mitigation.

## What this does to a shortlist

If second-site capability is a baseline expectation, it changes how a shortlist gets built in three ways.

**Footprint becomes a scoring criterion, not a footnote.** A [sponsored [Piramal Pharma Solutions](/companies/piramalpharmasolutions) piece](https://www.pharmaceutical-technology.com/sponsored/what-matters-in-the-api-market-as-2026-approaches/) pitches a footprint of multiple development and manufacturing sites across continents as alignment with shifting sponsor expectations. It is marketing, but it shows how CDMOs now position themselves. Expect more bids to lead with geography. A multi-site footprint helps only if the sites are actually qualified for your process, which brings us to the next point.

**"We have another site" is not the same as "that site is ready."** The cdmo.directory source says second-site qualification, not mere second-site existence, is the expectation. Here I am reasoning beyond the sources, but the logic is straightforward. Qualification means technology transfer, analytical method transfer, validation or comparability work, and regulatory filings that name the site. A site that exists on a vendor's capability slide is not a contingency until those steps are done and your filings reflect them.

**The market is not giving buyers much slack.** Vision Life Sciences cites Precedence Research estimates of a CDMO market growing at roughly 7% a year in 2026, and notes that the landscape is being reshaped by geopolitical forces. The excerpt gives no capacity data specific to API, so I would not conclude that second-site slots are scarce. Still, growth plus realignment suggests that buyers who decide late will be competing for the same alternatives as everyone else who is moving away from concentrated sourcing.

## Where the evidence runs out

A buyer should know what these sources do not say:

- No cost figures for dual sourcing or second-site qualification. The cost of carrying two qualified sites is the first thing finance will ask about, and nothing here answers it.
- No timelines. How long a transfer takes depends heavily on chemistry, route complexity, and regulatory pathway.
- No incident data. The sources describe risk and direction, not a count of disrupted API supply events.
- No view of upstream concentration. They mention intermediates only in passing.
- Limited independence. Two of the eight sources share identical text, one is sponsored, one is a press release, and one is the directory's own earlier commentary.

None of this undercuts the direction of travel. It does mean that the argument for a second site should be built on your own program's exposure, not on the generalities in trade commentary.

## Questions worth putting in the next RFP

The goal is to turn a general resilience claim into something you can score. These questions follow from the sources' themes but are my framing.

1. **Which sites are qualified for this molecule, and which are only listed?** Ask for the status of each: process transferred, validated, named in a filing, or none of the above.
2. **Where do the starting materials and key intermediates come from?** Ask for country of origin by step and whether any step depends on a single supplier. The Almanac's reference to intermediates is the reason to ask.
3. **How does the vendor's footprint interact with BIOSECURE-type restrictions?** Ask whether any site, parent, or critical subcontractor could raise a policy question for a US-bound program, and get the answer in writing. Do not rely on a sales summary.
4. **What happens to your slot if a site goes down?** Ask whether failover to another site is contractual, what the notice and prioritization terms are, and who bears the comparability work.
5. **Who pays for the second site, and when?** Qualification before launch costs more up front but is cheaper than an emergency transfer. Ask the vendor to price both paths so your team can compare them.
6. **Can you run scenarios with the vendor?** The cdmo.directory source highlights scenario-based contingency planning. A vendor that can walk through a sanctions, port, or export-control scenario for your product has probably thought about it. One that cannot is telling you something.
7. **What does regulatory divergence mean for this program?** For programs touching China-based capacity, PeptideStaff flags divergence as a distinct risk. Ask how specification, inspection, and filing differences would be handled across the two sites.

## What to do before the next award

Decide the resilience posture before you score vendors, not after. Specifically: set a requirement for a qualified second site, or a funded plan to qualify one, and put it in the RFP as a gate rather than a bonus. Then you can compare bids on equal terms, instead of discovering mid-evaluation that one vendor's price assumes a single site.

Separate the policy question from the operational one. BIOSECURE exposure is a legal and strategic matter that may remove a vendor outright for certain programs. Disruption risk from trade disputes or instability is an operational matter that affects every vendor to some degree. Mixing them leads to vague scoring.

Finally, be honest with your own leadership about the evidence. The direction is consistent across sources, but much of it is commentary, and the cost side is unquantified. The strongest case for a second site will come from your program's own data: how long you can tolerate a gap in supply, how concentrated your upstream materials are, and which markets you serve.

## Sources

1. API CDMOs [Navigate Geopolitical Risk: Dual Sourcing](https://www.cdmo.directory/posts/api-cdmos-navigate-geopolitical-risk-dual-sourcing-supply-resilience-in-2026-cdmo) & Supply Resilience in 2026 (cdmo.directory)
2. What matters in the API market as [2026 approaches (Pharmaceutical Technology, sponsored)](https://www.pharmaceutical-technology.com/sponsored/what-matters-in-the-api-market-as-2026-approaches/)
3. Impact of Geopolitical Tensions, Sanctions, and Supply Chain [Disruptions on Contract Manufacturing (PharmiWeb)](https://www.pharmiweb.com/press-release/2026-04-13/impact-of-geopolitical-tensions-sanctions-and-supply-chain-disruptions-on-contract-manufacturing-cdmocmo-and-pharma-outsourcing-trends)
4. Top [Threats Facing the CDMO Industry](https://vectorbiomed.com/resource/what-do-you-see-as-the-biggest-threat-to-the-cdmo-industry-in-2026-or-beyond/) in 2026 and Beyond (Vector Biomed)
5. China [Peptide CDMO Market: Risk Analysis](https://peptidestaff.com/news/china-peptide-cdmo-risk-analysis-2026/) for Western Pharma Clients in 2026 (PeptideStaff)
6. How are geopolitical factors [influencing sourcing and manufacturing decisions](https://www.pharmasalmanac.com/articles/how-are-geopolitical-factors-influencing-sourcing-and-manufacturing-decisions-for-2026-and-beyond) for 2026 and beyond? (Pharma's Almanac)
7. What do you see as the biggest threat to the CDMO industry in [2026 or beyond? (Pharma's Almanac)](https://www.pharmasalmanac.com/articles/what-do-you-see-as-the-biggest-threat-to-the-cdmo-industry-in-2026-or-beyond)
8. CDMO [Market Analysis 2026: Size, Trends](https://visionlifesciences.com/insights/cdmo-market-analysis) & Key Players (Vision Life Sciences)

Source: https://www.cdmo.directory/posts/geopolitics-is-turning-second-site-qualification-into-a-baseline-api-cdmo-requirement-in-cdmo